[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338394-105":59,"doc-detail-338394-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-first-in-class-wiskott-aldrich-syndrome-protein-activator-with-antitumor-activity-in-hematologic-cancers","A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers","","Hematologic cancers remain highly lethal despite major therapeutic advances, with many patients ultimately succumbing to relapse and resistance. The Wiskott-Aldrich syndrome protein (WASp) family controls actin assembly with the Arp2/3 complex and is limited to hematopoietic cells in autoinhibited and activated states. The study develops EG-011, a first-in-class small molecule that activates autoinhibited WASp. EG-011 shows single-agent antitumor activity across lymphoma, leukemia, and multiple myeloma, including models with secondary resistance to PI3K, BTK, and proteasome inhibitors. Multiple methods confirm actin polymerization and WASp binding, while transcriptome analysis supports pathways linked to actin-polymerizing drugs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-first-in-class-wiskott-aldrich-syndrome-protein-activator-with-antitumor-activity-in-hematologic-cancers/338394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-first-in-class-wiskott-aldrich-syndrome-protein-activator-with-antitumor-activity-in-hematologic-cancers/338394.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is EG-011 and what biological target does it act on?","Question",{"text":112,"@type":113},"EG-011 is a first-in-class small molecule activator designed to activate the autoinhibited form of the Wiskott-Aldrich syndrome protein (WASp).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which hematologic cancer types show antitumor activity with EG-011?",{"text":117,"@type":113},"EG-011 demonstrates in vitro and in vivo antitumor activity as a single agent in lymphoma, leukemia, and multiple myeloma.",{"name":119,"@type":110,"acceptedAnswer":120},"How was EG-011’s mechanism evaluated in the study?",{"text":121,"@type":113},"Actin polymerization and WASp binding were assessed using multiple techniques, and transcriptome analysis supported homology with drugs that induce actin polymerization.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338394,1790789768,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ARTICLE-Non-Hodgkin Lymphoma  \nA first-in-class Wiskott-Aldrich syndrome protein  \nactivator with antitumor activity in hematologic cancers  \nFilippo Spriano1,+ Giulio Sartori1, Jacopo Sgrignani,2 Laura Barnabei1, Alberto J. Arribas,1,3 Matilde Guala,4 Ana Maria Carrasco Del Amor,5 Meagan R. Tomasso,6 Chiara Tarantelli1, Luciano Cascione,1,3 Gaetanina Golino,1,7 Maria E. Riveiro,8 Roberta Bortolozzi,9,10 Antonio Lupia,7,11 Francesco Paduano,12,13 Samuel Huguet1,4 Keyvan Rezai1,4 Andrea Rinaldi1, Francesco Margheriti1, Pedro Ventura,2 Greta Guarda,2 Giosuè Costa1,2 Roberta Rocca1,2 Alberto Furlan,2 Luuk M. Verdonk1,5 Paolo Innocenti1,5 Nathaniel I. Martin1,5 Giampietro Viola,9,10 Christoph Driessen1,6 Emanuele Zucca,1,17 Anastasios Stathis1,7 Digvijay Gahtory1,8 Maurits van den Nieuwboer1,8 Beat Bornhauser1,9 Stefano Alcaro1,2 Francesco Trapasso1,2 Susana Cristobal,5,20 Shae B. Padrick,6 Natalina Pazzi,4 Franco Cavalli1, Andrea Cavalli,2 Eugenio Gaudio1+ and Francesco Bertoni1,17  \n1 Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; 2 Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; 3SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland;  \n4Chimete, Tortona, Italy; 5 Department of Biomedical and Clinical Sciences, Cell Biology, Medical Faculty, Linköping University, Linköping, Sweden; 6 Drexel University, College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, PA, USA; 7 Department of Pharmacy, University of Napoli Federico II, Napoli, Italy; 8 Early Drug Development Group, Boulogne-Billancourt, France; 9 Department of Woman’s and Child’s Health, University of Padova, Padova, Italy; 10 Istituto di Ricerca Pediatrica IRP, Fondazione Città della Speranza, Padova, Italy; 11 Net4science Srl, Magna Graecia University of Catanzaro, Catanzaro, Italy; 12 University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 13Tecnologica Research Institute and Marrelli Health, Biomedical Section, Stem Cells and Medical Genetics Units, Crotone, Italy; 14 Institut Curie, Paris, France; 15 Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden, the Netherlands; 16 Kantosspital St Gallen, St Gallen, Switzerland; 17Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 18 BIMINI Biotech B.V., Leiden, the Netherlands;  \n19Children’s Hospital Zurich, Zurich, Switzerland; 20 Ikerbasque, Basque Foundation for Sciences, Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, Bilbao, Spain  \nCorrespondence: E. Gaudio  \n[eugaudio1976@gmail.com](eugaudio1976@gmail.com)  \nF. Bertoni  \n[francesco.bertoni@ior.usi.ch](francesco.bertoni@ior.usi.ch)  \nReceived: December 31, 2022.  \nAccepted: June 7, 2024.  \nEarly view: June 20, 2024.  \n[https://doi.org/10.3324/haematol.2022.282672](https://doi.org/10.3324/haematol.2022.282672)  \n©2024 Ferrata Storti Foundation  \nPublished under a CC BY-NC license   \n+FS and EG contributed equally to this work.  \nAbstract  \nHematologic cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family regulates actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic cells and exists in two allosteric conformations: autoinhibited or activated. Here, we describe the development of EG-011, a first-in-class small molecule activator of the autoinhibited form of WASp. EG-011 possesses in vitro and in vivo antitumor activity as a single agent in lymphoma, leukemia, and multiple myeloma, including models of secondary resistance to PI3K, BTK, and proteasome inhibitors. The in vitro activity was confirmed in a lymphoma xenograft. Actin polymerization and WAS","cbCairBAlpWVwmXI","https://ap.wps.com/l/cbCairBAlpWVwmXI","pdf",3695485,13,"English","# Abstract\n# Introduction","[{\"question\":\"What is EG-011 and what biological target does it act on?\",\"answer\":\"EG-011 is a first-in-class small molecule activator designed to activate the autoinhibited form of the Wiskott-Aldrich syndrome protein (WASp).\"},{\"question\":\"Which hematologic cancer types show antitumor activity with EG-011?\",\"answer\":\"EG-011 demonstrates in vitro and in vivo antitumor activity as a single agent in lymphoma, leukemia, and multiple myeloma.\"},{\"question\":\"How was EG-011’s mechanism evaluated in the study?\",\"answer\":\"Actin polymerization and WASp binding were assessed using multiple techniques, and transcriptome analysis supported homology with drugs that induce actin polymerization.\"}]","A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers | PDF",1790023464,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/498cd387a657c15d60917cc8ea096822.webp",983,1309,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33f3dc18617ab0c3ed190a89a57506c3.webp",982,1308,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c84e1e8e2691487ef9d2b38003c74b78.webp",981,1306,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ab0587e1d48fffab357011858aaa797.webp",980,1305]